Jounce Therapeutics Inc (NASDAQ:JNCE) saw a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 533,900 shares, an increase of 19.0% from the June 30th total of 448,500 shares. Based on an average trading volume of 182,400 shares, the days-to-cover ratio is currently 2.9 days. Currently, 3.7% of the shares of the company are short sold.
Shares of NASDAQ JNCE traded down $0.14 during trading on Wednesday, hitting $4.11. The company had a trading volume of 110,100 shares, compared to its average volume of 201,931. The company has a 50 day simple moving average of $4.45. The company has a quick ratio of 2.03, a current ratio of 2.03 and a debt-to-equity ratio of 0.20. Jounce Therapeutics has a 12 month low of $2.66 and a 12 month high of $8.58. The company has a market capitalization of $138.20 million, a price-to-earnings ratio of -4.89 and a beta of 3.44.
Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.05. Jounce Therapeutics had a negative return on equity of 29.64% and a negative net margin of 46.07%. The firm had revenue of $17.45 million for the quarter, compared to the consensus estimate of $17.09 million. Equities analysts anticipate that Jounce Therapeutics will post 0.72 EPS for the current fiscal year.
Separately, JPMorgan Chase & Co. reissued a “sell” rating on shares of Jounce Therapeutics in a report on Sunday. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $10.00.
Several hedge funds and other institutional investors have recently bought and sold shares of JNCE. Meeder Asset Management Inc. raised its stake in shares of Jounce Therapeutics by 249.6% in the second quarter. Meeder Asset Management Inc. now owns 5,034 shares of the company’s stock worth $25,000 after buying an additional 3,594 shares during the period. A.R.T. Advisors LLC bought a new position in shares of Jounce Therapeutics in the second quarter worth about $59,000. Raymond James & Associates bought a new position in shares of Jounce Therapeutics in the fourth quarter worth about $71,000. Algert Global LLC purchased a new stake in shares of Jounce Therapeutics during the first quarter worth about $88,000. Finally, Bailard Inc. purchased a new stake in shares of Jounce Therapeutics during the first quarter worth about $92,000. 73.54% of the stock is currently owned by hedge funds and other institutional investors.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Further Reading: Investing strategies using the yield curve
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.